HOUSTON, Jan. 29, 2018 /PRNewswire/ -- Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the appointment of Michael Brawer, M.D., as Chief Medical Officer (CMO). Dr. Brawer will assume responsibility for leading Nanospectra's overall clinical development, regulatory, and medical affairs activities, effective immediately. He will work in tandem with and report directly to David Jorden, Chief Executive Officer, and join the company's executive leadership team.
"Michael is an internationally recognized expert in prostate cancer and urology and represents an important addition to our leadership team," said David Jorden, CEO of Nanospectra. "His extensive experience in prostate cancer research, development and clinical care in both U.S. and international markets, will be instrumental in helping effectively and appropriately commercialize our AuroLase Therapy."
For the past 30 years, Dr. Brawer has worked at top-tier research institutions and leading life science corporations throughout the United States, most recently serving as CMO of MDx Health. Prior to joining MDx Health, Dr. Brawer served as senior vice president, medical affairs urology at Myriad Genetics Laboratories where he led all clinical aspects of development, education and commercialization of Prolaris, a prostate cancer prognostic assay. Dr. Brawer has also held numerous faculty appointments culminating in the position of Director, Northwest Prostate Institute where he led the Institute focused on multidisciplinary clinical practice, community outreach, basic and clinical research and medical education.
Dr. Brawer holds a Bachelor of Arts degree from University of California, Los Angeles, where he also received his M.D. degree. He completed his surgery and urology residencies at Stanford University Medical Center. A prolific researcher and author, he has published more than 200 scientific papers, 10 books, 74 book chapters, 18 editorials and 101 abstracts.
"There is currently a meaningful unmet need for methods to treat low to intermediate grade prostate cancer without causing undue morbidity to the patient," said Dr. Brawer. "Nanospectra's AuroLase technology for focal therapy has the potential to be highly effective with little or no morbidity while also maintaining the opportunity for future procedures should retreatment be needed. With 33 patients now enrolled and treated in the initial 45 patient pilot study, I am excited to join the company and help bring this important new tool to clinicians and patients."
About Nanospectra Biosciences
Nanospectra Biosciences is a privately-held medical device company, pioneering the patient-centric use of nanomedicine for selective thermal ablation. AuroLase®, the company's lead product, is the first ultra-focal therapy for prostate cancer. Nanospectra's ultra-focal approach maximizes treatment efficacy while minimizing side effects associated with current treatments, including surgery, radiation, and traditional focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectra's technology development has been funded to date by a series of grants, private equity investments and corporate partnerships. For more information visit http://www.nanospectra.com.